Kuros Biosciences AG
CSBTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $75,555 | $33,564 | $17,986 | $13,815 |
| % Growth | 125.1% | 86.6% | 30.2% | – |
| Cost of Goods Sold | $13,524 | $5,093 | $7,217 | $3,749 |
| Gross Profit | $62,031 | $28,471 | $10,769 | $10,066 |
| % Margin | 82.1% | 84.8% | 59.9% | 72.9% |
| R&D Expenses | $6,984 | $5,599 | $5,194 | $4,989 |
| G&A Expenses | $5,077 | $3,555 | $3,069 | $2,582 |
| SG&A Expenses | $41,257 | $20,691 | $11,153 | $7,381 |
| Sales & Mktg Exp. | $36,180 | $17,134 | $8,084 | $4,799 |
| Other Operating Expenses | $18,785 | $15,373 | $7,868 | $6,463 |
| Operating Expenses | $67,026 | $41,663 | $24,215 | $18,833 |
| Operating Income | -$4,995 | -$13,192 | -$13,446 | -$8,767 |
| % Margin | -6.6% | -39.3% | -74.8% | -63.5% |
| Other Income/Exp. Net | $1,649 | $3,416 | -$2,545 | -$787 |
| Pre-Tax Income | -$3,346 | -$9,776 | -$15,991 | -$9,554 |
| Tax Expense | $370 | $380 | -$1,396 | -$2,013 |
| Net Income | -$3,716 | -$13,727 | -$14,595 | -$7,541 |
| % Margin | -4.9% | -40.9% | -81.1% | -54.6% |
| EPS | -0.1 | -0.38 | -0.43 | -0.23 |
| % Growth | 73.7% | 11.6% | -87% | – |
| EPS Diluted | -0.1 | -0.38 | -0.43 | -0.23 |
| Weighted Avg Shares Out | 37,199 | 36,582 | 33,901 | 32,794 |
| Weighted Avg Shares Out Dil | 37,199 | 36,582 | 33,901 | 32,794 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $400 | $1,772 | $596 |
| Interest Expense | $149 | -$1,745 | $4,317 | $1,383 |
| Depreciation & Amortization | $2,636 | $2,096 | $2,346 | $2,880 |
| EBITDA | -$561 | -$7,494 | -$7,500 | -$5,291 |
| % Margin | -0.7% | -22.3% | -41.7% | -38.3% |